This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (105)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A Clinical and Immunopathologic Analysis

Aditya K. Gupta, MD, FRCP(C); Charles N. Ellis, MD; Brian J. Nickoloff, MD, PhD; Michael T. Goldfarb, MD; Vincent C. Ho, MD, FRCP(C); Leslie L. Rocher, MD; Christopher E. M. Griffiths, MB, MRCP; Kevin D. Cooper, MD; John J. Voorhees, MD

Arch Dermatol. 1990;126(3):339-350.

Abstract
• Cyclosporine is known to be effective in the treatment of psoriasis. In this study, we have used oral cyclosporine (6 mg/kg per day) given for 5 to 30 weeks to 24 patients for the treatment of 12 different dermatoses. Patients with the following diseases demonstrated a marked response or total clearing: 1 patient each with pyoderma gangrenosum, pityriasis lichenoides chronica, and psoriasis of the acrodermatitis continua of Hallopeau type. Moderate to marked response occurred in both patients with epidermolysis bullosa acquisita and the patient with hidradenitis suppurativa. Minimal to moderate responses were obtained in both patients with granuloma annulare, 1 of 2 with acrodermatitis continua of Hallopeau, both patients with Darier's disease, and 1 of 6 patients with vitiligo. Little or no response was noted in both patients with sarcoidosis, all 3 patients with pityriasis rubra pilaris, 5 of 6 patients with vitiligo, 1 patient with pemphigus foliaceous, and 1 with pemphigus vulgaris. Clinical side effects were mild and transient and included dysesthesia, fatigue, hypertrichosis, nausea, and flushing. The most frequent clinically significant abnormalities were hypertension and renal dysfunction, with all factors normalizing within 1 month of discontinuation of cyclosporine therapy.

(Arch Dermatol. 1990;126:339-350)

Author Affiliations
From the Departments of Dermatology (Drs Gupta, Ellis, Nickoloff, Goldfarb, Ho, Griffiths, Cooper, and Voorhees), Pathology (Dr Nickoloff), and Internal Medicine (Dr Rocher), the University of Michigan Medical School, Ann Arbor. Dr Gupta is now with the National Cancer Institute, National Institutes of Health, Bethesda, Md.

Footnotes
Accepted for publication September 5, 1989.

Reprint requests to Department of Dermatology, University of Michigan Medical Center, Room 1910, Taubman Center, 1500 E Medical Center Dr, Ann Arbor, MI 48109-0314 (Dr Voorhees).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Interventions for Mucous Membrane Pemphigoid/Cicatricial Pemphigoid and Epidermolysis Bullosa Acquisita: A Systematic Literature Review
Kirtschig et al.
Arch Dermatol 2002;138:380-384.
ABSTRACT | FULL TEXT  

Pityriasis Rubra Pilaris and Cyclosporine
Rosenbach and Lowe
Arch Dermatol 1993;129:1346-1348.
ABSTRACT  

Treatment of Pyoderma Gangrenosum With Cyclosporine
Matis et al.
Arch Dermatol 1992;128:1060-1064.
ABSTRACT  

Low-Dose Cyclosporine A in the Treatment of Disabling Morphea
Peter et al.
Arch Dermatol 1991;127:1420-1421.
ABSTRACT  

Short-term Changes in Renal Function, Blood Pressure, and Electrolyte Levels in Patients Receiving Cyclosporine for Dermatologic Disorders
Gupta et al.
Arch Intern Med 1991;151:356-362.
ABSTRACT